GO-JG-1 is a preclinical drug candidate that we believe irreversibly cross-links DNA. We anticipate that GO-JG-1 may have widespread clinical use, including for blood cancers (myeloma, lymphoma, and leukemia), brain cancer, eye cancers, and non-cancerous proliferative disorders of the eye.
Our discovery stage drugs include novel DNA cross-linking drugs designed to target solid tumors such as stage IV colon cancer and stage IV prostate cancer.
